This transcript has been edited for clarity. Kenneth Pienta, MD: Hi. I am Dr. Ken Pienta, and I'm joined by my nurse practitioner colleague, Diane Reyes-Dagher, for this CareCues conversation on how ...
A 68-year-old man presented to the emergency department with haematuria and penile pain. His medical history included benign prostatic hyperplasia, but no follow-up examinations had been performed.
Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer. The first patient has been dosed in a phase 1/2 trial ...
The PROSTATE-IQ trial uses the ArteraAI Prostate Test to personalize treatment for prostate cancer recurrence post-prostatectomy, potentially reducing hormone therapy use. The trial stratifies ...
The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE:NVS) Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of ...
AI could eliminate the "postcode lottery" surrounding a life-extending treatment for advanced prostate cancer, researchers have said. A recent study found that AI can identify patients who will ...
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track ...
10monon MSNOpinion
One test could have prevented terminal prostate cancer, says patient
One test could have prevented terminal prostate cancer, says patient - Research has shown that the use of the PSA test varies ...
A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback